ROYALTY PHARMA PLC- CL A (RPRX)
GB00BMVP7Y09 - Common Stock
Royalty Pharma Appoints Molly Sawaya as Executive Vice President, Head of Human Capital
Royalty Pharma Appoints Molly Sawaya as Executive Vice President, Head of Human Capital
NEW YORK, July 24, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced the appointment of Molly Sawaya as Executive Vice...
Royalty Pharma to Announce Second Quarter 2024 Financial Results on August 8, 2024
Royalty Pharma to Announce Second Quarter 2024 Financial Results on August 8, 2024
NEW YORK, July 19, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its second quarter 2024 financial...
Royalty Pharma Declares Third Quarter 2024 Dividend
Royalty Pharma Declares Third Quarter 2024 Dividend
NEW YORK, July 17, 2024 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the...
Cytokinetics' Wild Ride: Can Investors Forgive The Royalty Pharma Deal?
CEO Robert Blum says there are key components to the funding arrangement with Royalty Pharma that investors are missing.
Wall Street Favorites: 3 Biotech Stocks With Strong Buy Ratings for June 2024
Selecting strong buy biotech stocks isn’t easy when most of them don’t make money. Here are three possibilities to meet this challenge.
7 Biotech Stocks to Buy on the Dip: June 2024
With health being a top priority over wealth generation, these biotech stocks to buy on the dip enjoy a sound framework for speculation.
June’s Biotech Boom: 3 Stocks to Buy for a Summertime Surge
Biotech surge alert! Discover three biotech stocks to buy as they catch up with the market in the rest of 2024.
Royalty Pharma to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
Royalty Pharma to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
NEW YORK, June 04, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it is scheduled to participate in a fireside chat at...
Royalty Pharma Announces Pricing of $1.5 Billion of Senior Unsecured Notes
Royalty Pharma Announces Pricing of $1.5 Billion of Senior Unsecured Notes
NEW YORK, June 03, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) announced today that it has priced an offering of $1.5 billion of senior...
Agios Pharmaceuticals Inks $905 Million Deal For Cancer Drug; Shares Poised To Break Out
The stock is poised to break out of a cup-with-handle base after inking a deal for a cancer drug.
Royalty Pharma and Agios Pharmaceuticals Enter Into Vorasidenib Royalty Agreement for $905 Million
Royalty Pharma and Agios Pharmaceuticals Enter Into Vorasidenib Royalty Agreement for $905 Million
Vorasidenib, if approved, would be the first targeted therapy in IDH-mutant glioma, a progressive and incurable brain tumorPivotal Phase 3 clinical study...
Royalty Pharma Larger Than S&P 500 Component Insulet
Royalty Pharma and Cytokinetics Announce Expanded Strategic Funding Collaboration Totaling Up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D Pipeline
Royalty Pharma and Cytokinetics Announce Expanded Strategic Funding Collaboration Totaling Up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D Pipeline
Deal provides Cytokinetics with diversified access to capital as company advances its specialty cardiology franchise NEW YORK and SOUTH SAN FRANCISCO,...
7 Dividend Stocks to Buy at a 52-Week Low
For steady yields, not to mention rebound potential, consider the following seven dividend stocks at a 52-week low.
Royalty Pharma to Present at Upcoming Investor Conferences
Royalty Pharma to Present at Upcoming Investor Conferences
NEW YORK, May 13, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in the following upcoming investor...
RPRX Stock Earnings: Royalty Pharma Misses EPS, Misses Revenue for Q1 2024
RPRX stock results show that Royalty Pharma missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.
Royalty Pharma Reports First Quarter 2024 Results
Royalty Pharma to Acquire Royalty Interest in Sanofi’s Frexalimab
Royalty Pharma to Acquire Royalty Interest in Sanofi’s Frexalimab
Frexalimab is in Phase 3 development by Sanofi in multiple sclerosis with multi-blockbuster potential in a wide range of immune-mediated diseasesExpands...
Royalty Pharma to Announce First Quarter 2024 Financial Results on May 9, 2024
Royalty Pharma to Announce First Quarter 2024 Financial Results on May 9, 2024
NEW YORK, April 19, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its first quarter 2024 financial...
Royalty Pharma Declares Second Quarter 2024 Dividend
Royalty Pharma Declares Second Quarter 2024 Dividend
NEW YORK, April 17, 2024 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the...
Relative Strength Alert For Royalty Pharma
3 Pharma Stocks to Sell in April Before They Crash & Burn
Discover three pharma stocks to sell in April, facing challenges and signaling potential for significant downside.
Billionaire Bargain Bin: 3 Stocks the Forbes 400 Loves (That You’ve Never Heard Of)
These Forbes 400 stocks have wealthy founders who run them with little fanfare or attention but are worth considering for your portfolio.
April’s Hidden Gems: 3 Overlooked Stocks to Freshen Up Your Portfolio
Discover three overlooked stocks on Wall Street with the potential for growth and diversification this April.